Literature DB >> 11473998

Improved antimicrobial interventions have benefits.

J Barenfanger1, M A Short, A A Groesch.   

Abstract

Studies have shown benefits to patients from improved interventions involving antimicrobial therapy. The purpose of the present study was to evaluate prospectively the impact of improved interventions by (i) the use of TheraTrac 2, a computer software program which electronically links susceptibility testing results immediately to the pharmacy and alerts pharmacists of potential interventions, and (ii) the education of pharmacists involving microbiologic topics. The study group had the new intervention program. The control group had interventions performed the way that they had previously been done by manually reviewing hard copies of susceptibility testing data. In a 5-month period, all inpatients whose last names began with A to K were the study group; inpatients whose last names began with L to Z were controls. Three analyses were done; one analysis (analysis A) involved only patients with interventions, one analysis (analysis B) involved all patients for whom antimicrobial testing was done and who were matched for diagnosis-related groups (DRGs), regardless of whether an intervention occurred, and one analysis (analysis C) involved these DRG-matched patients by using severity-adjusted data. In analysis A, the study group had a 4.8% decreased rate of mortality, an average of a 16.5-day decreased length of stay per patient, and $20,886 decreased variable direct costs per patient. None of these differences was statistically significant. In analysis B, the study patients had a 1.2% higher mortality rate (P = 0.741), an average of a 2.7-day decreased length of stay per patient (P = 0.035), and $2,626 decreased variable direct costs per patient (P = 0.008). In analysis C, the study patients had a 1.4% lower mortality rate, a 1.2-day decreased length of stay per patient, and $1,466 decreased variable direct costs per patient. In conclusion, the institution of this program caused substantial cost savings.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11473998      PMCID: PMC88245          DOI: 10.1128/JCM.39.8.2823-2828.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Clinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing.

Authors:  J Barenfanger; C Drake; G Kacich
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

2.  Improving empiric antibiotic selection using computer decision support.

Authors:  R S Evans; D C Classen; S L Pestotnik; H P Lundsgaarde; J P Burke
Journal:  Arch Intern Med       Date:  1994-04-25

3.  A computer-assisted management program for antibiotics and other antiinfective agents.

Authors:  R S Evans; S L Pestotnik; D C Classen; T P Clemmer; L K Weaver; J F Orme; J F Lloyd; J P Burke
Journal:  N Engl J Med       Date:  1998-01-22       Impact factor: 91.245

4.  A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team.

Authors:  J G Gums; R W Yancey; C A Hamilton; P S Kubilis
Journal:  Pharmacotherapy       Date:  1999-12       Impact factor: 4.705

5.  Computer-assisted antimicrobial surveillance in a community teaching hospital.

Authors:  E T Jozefiak; J E Lewicki; W P Kozinn
Journal:  Am J Health Syst Pharm       Date:  1995-07-15       Impact factor: 2.637

6.  Computer-assisted concurrent antibiotic review in a community hospital.

Authors:  P D Scarafile; B D Campbell; J E Kilroy; H O Mathewson
Journal:  Am J Hosp Pharm       Date:  1985-02

7.  Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory.

Authors:  J J Schentag; C H Ballow; A L Fritz; J A Paladino; J D Williams; T J Cumbo; R V Ali; V A Galletta; M B Gutfeld; M H Adelman
Journal:  Diagn Microbiol Infect Dis       Date:  1993 Mar-Apr       Impact factor: 2.803

8.  Clinical impact of rapid in vitro susceptibility testing and bacterial identification.

Authors:  G V Doern; R Vautour; M Gaudet; B Levy
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

9.  Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes.

Authors:  S L Pestotnik; D C Classen; R S Evans; J P Burke
Journal:  Ann Intern Med       Date:  1996-05-15       Impact factor: 25.391

  9 in total
  12 in total

Review 1.  The economics of health information technology in medication management: a systematic review of economic evaluations.

Authors:  Daria O'Reilly; Jean-Eric Tarride; Ron Goeree; Cynthia Lokker; K Ann McKibbon
Journal:  J Am Med Inform Assoc       Date:  2011-10-07       Impact factor: 4.497

2.  Analysis of the comparative workflow and performance characteristics of the VITEK 2 and Phoenix systems.

Authors:  U Eigner; A Schmid; U Wild; D Bertsch; A-M Fahr
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

3.  Use of PCR coupled with electrospray ionization mass spectrometry for rapid identification of bacterial and yeast bloodstream pathogens from blood culture bottles.

Authors:  Erin J Kaleta; Andrew E Clark; Desiree R Johnson; Dulini C Gamage; Vicki H Wysocki; Abdessalam Cherkaoui; Jacques Schrenzel; Donna M Wolk
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

4.  Comparison of BD phoenix to vitek 2, microscan MICroSTREP, and Etest for antimicrobial susceptibility testing of Streptococcus pneumoniae.

Authors:  Scott A Mittman; Richard C Huard; Phyllis Della-Latta; Susan Whittier
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

5.  Effects of an operational multidisciplinary team on hospital antibiotic use and cost in France: a cluster controlled trial.

Authors:  Sibylle Bevilacqua; Béatrice Demoré; Marie-Line Erpelding; Emmanuelle Boschetti; Thierry May; Isabelle May; Christian Rabaud; Nathalie Thilly
Journal:  Int J Clin Pharm       Date:  2011-03-25

6.  The value of outcomes data in the practice of clinical microbiology.

Authors:  Gary V Doern
Journal:  J Clin Microbiol       Date:  2014-03-12       Impact factor: 5.948

Review 7.  Clinical and economic outcomes of pharmaceutical services related to antibiotic use: a literature review.

Authors:  Vera von Gunten; Jean-Philippe Reymond; Johnny Beney
Journal:  Pharm World Sci       Date:  2007-02-02

8.  Evaluation of the MicroScan MICroSTREP plus antimicrobial panel for testing β-hemolytic streptococci and viridans group streptococci.

Authors:  Sung Ju Kim; Young Uh; In Ho Jang; Kwan Soo Lee; Soon Deok Park; Kap Jun Yoon
Journal:  Korean J Lab Med       Date:  2011-06-28

9.  A cost-benefit analysis of twice-daily consultant ward rounds and clinical input on investigation and pharmacy costs in a major teaching hospital in the UK.

Authors:  Aftab Ahmad; Philip J Weston; Mahin Ahmad; Dushyant Sharma; Tejpal Purewal
Journal:  BMJ Open       Date:  2015-04-08       Impact factor: 2.692

Review 10.  Educational interventions to improve prescription and dispensing of antibiotics: a systematic review.

Authors:  Fátima Roque; Maria Teresa Herdeiro; Sara Soares; António Teixeira Rodrigues; Luiza Breitenfeld; Adolfo Figueiras
Journal:  BMC Public Health       Date:  2014-12-15       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.